Background. A new formulation of tenofovir with alafenamide (TAF) has been introduced that promises to reduce the risk of renal disease. However, the clinical impact of TAF in elderly persons with HIV/AIDS and comorbid renal disease has not been fully investigated. Using patient data from Louis Stokes Cleveland VA Medical Center, this study examines the effect of TDF discontinuation on renal function.
Methods. With IRB approval, clinical data from 272 veterans with HIV/AIDS were gathered to estimate glomerular filtration rate (eGFR) using CKD-EPI (CE) and Cockcroft-Gault (CG) formulae.
Results. 122 patients were excluded because they did not meet the criteria for the study or for insufficient data. The remaining 150 patients had a mean age of 57.7 years, 96.7% were male, 51% African American, 50% were smokers, 28% had diabetes and 63% had vascular disease risk factors. Baseline mean sCR value was 1.1 ± 0.3. Mean CD4 was 672 ± 372 on TDF containing regimens (703 ± 344 after switch) and 66% (69%) had viral loads <20 cp/mL. Serum creatinine (sCr) values before and after the discontinuation of TDF were collected, and eGFR and rate of change for eGFR and sCr were calculated. In a univariate manner, variables were also examined within 3 subgroups: smokers, diabetics and patients with vascular disease risk factors. Changes in boosting medication were rare (5 patients started cobicistat and 7 patients discontinued ritonavir) and thus had little effect on average changes in sCr and eGFR in this cohort. Overall, discontinuation of TDF stabilized sCR (Figure 1 ). Mean sCr increased by 0.13 and eGFR declined by 5.755 (CE) or 11.822 (CG) during the mean 181 days of observation prior to TDF discontinuation. After the switch, mean sCr increased by 0.002 during a mean of 396 days of observation; eGFR increased by 1.198 (CE) or 1.300 (CG). Similar trends were observed in the 3 subgroups. In all groups, discontinuation of TDF led to improvement in eGFR.
Conclusion. Discontinuation of TDF and initiation of TAF or other non TDF containing regimen stabilizes eGFR in elderly men with HIV and underlying risk for renal disease. 
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HIV Transplantation Awareness and Attitudes Following Implementation of the HOPE Act
Background.
As HIV infection has evolved from a highly morbid diagnosis to a functionally chronic condition, comorbid conditions including liver and kidney failure have become more prevalent. Limited organ availability prevents many persons living with HIV (PLWH) from having an opportunity for transplantation. Inclusion of PLWH as organ donors is uniquely suited to increasing access to life saving grafts. Here, we sought to assess the awareness of the HOPE Act in PLWH, and determine whether providing information on the HOPE Act and HIV to HIV transplantation increased support for becoming an organ donor.
Methods. Using a computer interface, we surveyed 200 patients in an HIV clinic and assessed their awareness of the HOPE Act and attitudes toward transplantation. Incorporated into the survey was a brief explanation of the HOPE Act and background into HIV to HIV transplantation. The information provided during the survey functioned as an intervention, and we again asked participants about their willingness to be an organ donor at the end of the survey.
Results. Over 75% of survey participants indicated support for organ transplantation in general, but less than 50% participants were willing to be listed as organ donors. 85% responded that they did not know whether PLWH were allowed to be an organ donor, and 94% were not familiar with the HOPE Act. However, 80% of respondents reported they would be willing to accept an organ from an HIV-infected donor. Support for organ donation increased to 60% after information about the HOPE Act and HIV transplantation was provided during the survey. Comparison of responses from before and after the intervention resulted in a kappa statistic of 0.42, indicating a change in opinion before and after the survey.
Conclusion. HIV-infected persons are at particularly high risk for organ failure. Most HIV-infected patients were unaware of HIV to HIV transplantation as a possibility and were reluctant to agree to become an organ donor. However, with this very brief, passive intervention, attitude toward transplantation improved. These findings suggest that informing PLWH about the HOPE Act and becoming an organ donor would be beneficial as HIV to HIV transplantation becomes more available.
Background. Our recent study showed significantly lower bone mineral content (BMC) in HIV-exposed uninfected (HEU) neonates born to HIV-infected (HIV+) mothers who took tenofovir disoproxil fumarate (TDF) in late pregnancy compared with no TDF use. In this cohort we sought to understand possible mechanisms for lower BMC by comparing markers of bone metabolism and renal function with TDF exposure in HEU neonates.
Methods. Among a subset of HEU children in the multicenter (United States and Puerto Rico) observational Surveillance Monitoring for ART Toxicities (SMARTT) Cohort study, we enrolled neonates (≥36 weeks gestational age) of HIV+ mothers who took TDF for ≥8 weeks in the third trimester (TDF+) or no TDF in pregnancy (TDF-). In addition to BMC measures, we collected a blood and urine sample on each child ≤30 days of birth to measure serum creatinine, phosphate, 25-OH vitamin D, parathyroid hormone and urine creatinine, phosphate and N-terminal telopeptide. Standard equations were used to estimate proximal tubular phosphate reabsorption and glomerular filtration rate (eGFR). Comparisons were made by TDF exposure using Wilcoxon and Fisher's exact tests. We fit linear models to compare TDF+ and TDF− for each assay by age in days at sample collection (slope), stratified by age group at sample collection time (0-3 days, 4-30 days).
Results. Of 160 HEU neonates (Black 71%, Hispanic 31%), 82 were TDF+ and 78 TDF−. Sociodemographic and anthropometric characteristics did not differ by TDF exposure in each age group. Within 0-3 days of life, TDF+ had a greater decline in serum creatinine (P = 0.04) and a greater increase in eGFR compared with TDF− (P = 0.06), but no difference in slope by TDF exposure within 4-30 days of life, nor in serum phosphate in either age group. Proximal tubular phosphate reabsorption was similar for both groups within the first 3 days of life, with a significantly greater decline in phosphate reabsorption between 4 and 30 days of life in the TDF+ compared with the TDF− group (P = 0.006, Figure 1 ). Bone markers did not differ by TDF exposure for either age group.
Conclusion. Urinary phosphate loss was increased among HEU neonates of mothers who took TDF in late pregnancy. This suggests proximal tubular dysfunction and may explain, at least in part, the decrease in BMC previously described.
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